Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 196

Sort by

Sort Order Select

Journal Articles

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Wassilis S. C. Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L. B. M. Korst, A. Vera de Jonge, Christie P. M. Verkleij, Rosa Rentenaar, Meliha Cosovic, Merve Eken, Inoka Twickler, Paola M. Homan-Weert, Pieter Sonneveld, Philippe Moreau, Jürgen Claesen, Niels W. C. J. van de Donk, Sonja Zweegman, Tuna Mutis

Blood (2025) 146 (21): 2517–2530.

https://doi.org/10.1182/blood.2025028587

Published: 2025

Includes: Supplemental data

Journal Articles

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study

Sonja Zweegman, Fredrik Schjesvold, Alessandra Larocca, Sabrin Tahri, Chiara Pautasso, Gloria Aguilar, Pavel Smirnov, Katy Gray, Margaret Doyle, Mario Boccadoro, Pieter Sonneveld, Niels W.C.J. Van De Donk, María-Victoria Mateos

Blood (2025) 146 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2025-4064

Published: 2025

Journal Articles

Determinants of response of the BCMA/GPRC5D-dual-targeting T-cell redirecting trispecific antibody JNJ-5322 in multiple myeloma

Chloe O Neill, Marloes Broekmans, Charlotte Korst, S Rubina Baglio, Maria Krevvata, Sonja Zweegman, Deeksha Vishwamitra, Tuna Mutis, Niels W.C.J. van de Donk

Blood (2025) 146 (Supplement 1): 3922.

https://doi.org/10.1182/blood-2025-3922

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood blood.2025030084.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

Blood (2025) 146 (6): 679–692.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Journal Articles

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Blood (2025) 145 (25): 3007–3014.

https://doi.org/10.1182/blood.2024026455

Published: 2025

Includes: Supplemental data

Journal Articles

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Blood (2025) 145 (5): 543–546.

https://doi.org/10.1182/blood.2024025868

Published: 2025

Includes: Supplemental data

Journal Articles

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Blood (2024) 144 (Supplement 1): 4739.

https://doi.org/10.1182/blood-2024-208754

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Blood (2024) 144 (Supplement 1): 362.

https://doi.org/10.1182/blood-2024-200871

Published: 2024

Journal Articles

CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence

Afroditi Katsarou, Georgios Kladis, Alexandros Nianias, Jiaxian Wang, Thomas Baardemans, Ruud Ruiter, Marie José Kersten, Sonja Zweegman, Tuna Mutis, Richard Groen, Maria Themeli

Blood (2024) 144 (Supplement 1): 2042.

https://doi.org/10.1182/blood-2024-208274

Published: 2024

Journal Articles

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Febe Smits, Kazem Nasserinejad, Mark-David Levin, Gert Jan Timmers, Esther G.M. De Waal, Josien C Regelink, Gerjo A. Velders, Matthijs Westerman, Nazik Durdu-Rayman, Suzanne Last-Koopmans, Roel JW van Kampen, Claudia A M Stege, Kaz Groen, Maarten R. Seefat, Monique C. Minnema, Pieter Sonneveld, Paula F Ypma, Niels W.C.J. van de Donk, Sonja Zweegman

Blood (2024) 144 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2024-203477

Published: 2024

Journal Articles

Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)

Charlotte L.B.M. Korst, Wouter Plattel, Elizabeth de Kort, Alexandra Croockewit, Mark-David Levin, Matthijs Westerman, Okke De Weerdt, Inger S. Nijhof, Jurgen Wegman, Nina Smit, Christie P.M. Verkleij, Tuna Mutis, Marjolein van der Klift, Laurens Franssen, Kaz Groen, Ellen van der Spek, Wilfried Roeloffzen, Sonja Zweegman, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2024-200187

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Blood (2024) 144 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2024-201448

Published: 2024

Journal Articles

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Annemiek Broijl, Fredrik Schjesvold, Abdel el Yaakoubi, Djamila Issa, Sonja Zweegman, Kon-Siong Jie, Mario Boccadoro, Roman Hajek, Bronno van der Holt, Ruth Wester, Pieter Sonneveld

Blood (2024) 144 (Supplement 1): 676.

https://doi.org/10.1182/blood-2024-209809

Published: 2024

Journal Articles

Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Blood (2024) 144 (Supplement 1): 898.

https://doi.org/10.1182/blood-2024-193310

Published: 2024

Journal Articles

Maintain maintenance in multiple myeloma?

Sonja Zweegman, Niels W. J. C. van de Donk

Blood (2023) 142 (18): 1501–1502.

https://doi.org/10.1182/blood.2023021781

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A T-cell–based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy

Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: The EMN37 fitfix study

Determinants of response of the BCMA/GPRC5D-dual-targeting T-cell redirecting trispecific antibody JNJ-5322 in multiple myeloma

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma - Long-Term Follow-up of the HOVON 143 Trial

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

CTLA-4-Based Activation Inducible Costimulatory Receptors Endow CAR-T Cells with Safe, Tumor-Restricted, Multi-Targeting and Increased Persistence

Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma

Long-Term Follow-up from the Phase 2 ICON Study of Iberdomide Combined with Low-Dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd)

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients

Maintain maintenance in multiple myeloma?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only